Orasis Pharmaceuticals leans into optometry to boost Qlosi adoption

To sustain this momentum, Orasis is rolling out two initiatives designed to keep the prescriber at the center of the patient journey. A new First Fill Free program, managed through the pharmacy partner BlinkRx, removes initial cost barriers for patients. Simultaneously, the company is authorizing in-office dispensing in states where regulations permit, allowing practitioners to provide the medication directly during a clinical visit.

Elad Kedar, CEO of Orasis, emphasized that the company’s strategy remains rooted in professional clinical relationships rather than direct-to-consumer digital platforms. Data from the field, according to the company, shows real-world safety and efficacy profiles consistent with Phase 3 clinical trials, with no reports of retinal detachments or tears filed with the FDA. For practitioners like David Rouse, president of the Florida Board of Optometry, these access options simplify the transition for patients struggling with age-related near-vision loss, providing a functional alternative to reading glasses.